Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian share markets slip further
Tue, 30 Jul 01:30 pm

Indian share markets were not enthused even as RBI kept interest rates unchanged and indicated a roll-back in tightening measures when the rupee gets stabilized. The share markets widened losses in the post-noon trading session. Barring IT, all the sectoral indices are trading in the red with realty, power and oil and gas stocks being the biggest losers.

BSE-Sensex is down 141 points and NSE-Nifty is trading 48 points down. BSE Mid Cap is trading down 1.4% and BSE Small Cap index is trading down 1.3%. The rupee is trading at 59.7 to the US dollar.

Majority of the FMCG stocks are trading in the green with Marico and Pidilite among the major gainers and Dabur and Colgate being the biggest losers. Colgate has announced its results for the quarter ended June 2013. The company recorded a 14.7% YoY rise in sales led by 9% YoY volume growth. Its toothpaste sales grew by a strong 11% during the quarter. However the company's operating margin contracted by 2.3% YoY to 19.2% due to a steep rise in other expenses that offset savings in input costs and wages (all as a proportion of sales). However at the net level, net profit surged by 58% on the back of exceptional income of Rs 555 m from slump sale of Global Shared Services Organization to its foreign parent company's wholly-owned subsidiary. During the quarter, the company has launched an innovative product 'Visible White' that prevents tooth surface stains for visibly white teeth.

Most of the Indian pharma stocks are trading in the red with Orchid Ltd and Dishman Pharma witnessing maximum selling pressures. Apotex a US based pharma company has recently received approval for Fenofibrate of 43mg and 160mg strengths from USFDA (United States Food and Drug Administration). This approval is equivalent to Lupin's brand Anatara. Some time back Mylan had launched the generics of the said drug. Apotex launch will further increase the competition and increase the price erosion. This will further impact Lupin's market share. It is still not clear whether Apotex has launched the drug or not. However as Mylan has already launched the generic of Antara, even Apotex launch can be expected in short time. Lupin generated annual revenues of US$ 60 m from the sale of this drug annually before Mylan's launch. Lupin was trading down by 1.93%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets slip further". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.